Preferred Label : risankizumab;
CISMeF synonym : BI 655066;
MeSH hyponym : risankizumab-rzaa; BI-655066;
UNII : 90ZX3Q3FR7;
Origin ID : C000601773;
UMLS CUI : C4505511;
ATC code(s)
Currated CISMeF NLP mapping
MeSH indexing information
MeSH term(s) associated for indexing
Record concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3501627/fr/skyrizi-risankizumab-maladie-de-crohn
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
infusions, intravenous
injections, subcutaneous
Interleukin Inhibitors
risankizumab
evaluation of the transparency committee
crohn disease
risankizumab
---
https://www.has-sante.fr/jcms/p_3539108/fr/skyrizi-risankizumab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
risankizumab
chronic disease
injections, subcutaneous
biological therapy
---
https://www.has-sante.fr/jcms/p_3426348/fr/skyrizi-risankizumab-maladie-de-crohn
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
risankizumab
adult
infusions, parenteral
injections, subcutaneous
evaluation of the transparency committee
crohn disease
risankizumab
---
https://www.has-sante.fr/jcms/p_3334262/fr/skyrizi-risankizumab-rhumatisme-psoriasique
2022
France
evaluation of the transparency committee
risankizumab
skyrizi
risankizumab
---
https://www.has-sante.fr/jcms/p_3363305/fr/skyrizi-risankizumab-psoriasis-en-plaques-de-l-adulte
2022
France
evaluation of the transparency committee
skyrizi
risankizumab
risankizumab
---
https://www.has-sante.fr/jcms/p_3273739/fr/skyrizi-risankizumab
2021
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
risankizumab
Product containing only risankizumab in parenteral dose form (medicinal product form)
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3117564/fr/skyrizi
2019
false
false
false
France
treatment outcome
injections, subcutaneous
psoriasis
adult
Interleukin-23
risankizumab
evaluation of the transparency committee
risankizumab
antibodies, monoclonal
---
https://www.ema.europa.eu/en/medicines/human/EPAR/skyrizi
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
adult
psoriasis
injections, subcutaneous
Interleukin-23
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
risankizumab
Product containing only risankizumab in parenteral dose form (medicinal product form)
risankizumab
risankizumab
antibodies, monoclonal
antibodies, monoclonal
---